Fremanezumab is indicated for prophylaxis of migraine in adults who have at least four migraine days per month.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||12/03/2019|
|Rapid review completed||17/04/2019|
|Rapid Review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of fremanezumab compared with the current standard of care, on the basis of the proposed price relative to currently available therapies. This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.|